Liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor-expressing glutamatergic neurons
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 receptor (GLP-1R) agonists are U.S. Food and Drug Administration–approved weight loss drugs. Despite their widespread use, the sites of action through which GLP-1R agonists (GLP1RAs) affect appetite and body weight are still not fully understood. We determined whether GLP-1Rs in either GABAergic or glutamatergic neurons are necessary for the short- and long-term effects of the GLP1RA liraglutide on food intake, visceral illness, body weight, and neural network activation. We found that mice lacking GLP-1Rs in vGAT-expressing GABAergic neurons responded identically to controls in all parameters measured, whereas deletion of GLP-1Rs in vGlut2-expressing glutamatergic neurons eliminated liraglutide-induced weight loss and visceral illness and severely attenuated its effects on feeding. Concomitantly, deletion of GLP-1Rs from glutamatergic neurons completely abolished the neural network activation observed after liraglutide administration. We conclude that liraglutide activates a dispersed but discrete neural network to mediate its physiological effects and that these effects require GLP-1R expression on glutamatergic but not GABAergic neurons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies have demonstrated that the principal sites of action accessible to these drugs are GLP-1R neurons in circumventricular organs, particularly the AP and ME, and those in immediately adjacent regions—the NTS and arcuate nucleus of the hypothalamus (16, 51, 63‐66).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs apparently only activate a subset of brainstem GLP-1R neurons, particularly in the NTS (65, 117).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 13,437
Primer3—new capabilities and interfaces
Untergasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B. C., Remm, M., & Rozen, S. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,461
The mouse brain in stereotaxic coordinates
Konsman, J.-P. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(03)00088-x · Cited by 4,045 · cited 5×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundInfluentialThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“GLP-1R is expressed in the pancreas, heart, kidney, gastrointestinal tract, and brain (1).”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“In rats, intracerebroventricular injection of a specific GLP-1R antagonist, exendin(9-39) has been shown to increase food intake in the short and long term, suggesting that neuronal GLP-1Rs contribute to normal feeding behavior (43,44).”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“As such, long-acting synthetic GLP-1R agonists (GLP1RAs) are useful therapeutic agents to treat type 2 diabetes (2).”
BackgroundLeptin Action on GABAergic Neurons Prevents Obesity and Reduces Inhibitory Tone to POMC Neurons
Vong, L., Ye, C., Yang, Z., Choi, B., Chua, S., & Lowell, B. B. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.028 · Cited by 1,235
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 7×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundInfluentialScrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 1×
“Indeed, whole-body Glp1r-knockout as well as pan-neuronal Glp1r-knockout mice exhibit normal food intake and bodyweight (6,42).”
BackgroundSensory neurons that detect stretch and nutrients in the digestive system
Williams, E. K., Chang, R. B., Strochlic, D. E., Umans, B. D., Lowell, B. B., & Liberles, S. D. (2016) · Cell · doi:10.1016/j.cell.2016.05.011 · Cited by 645 · cited 7×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
InfluentialSelf-citationAn excitatory paraventricular nucleus to AgRP neuron circuit that drives hunger
Krashes, M. J., Shah, B. P., Madara, J. C., Olson, D. P., Strochlic, D. E., Garfield, A. S., Vong, L., Pei, H., Watabe-Uchida, M., Uchida, N., et al. (2014) · Nature · doi:10.1038/nature12956 · Cited by 603 · cited 5×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundSelf-citationAbbott, C. R., Monteiro, M., Small, C. J., Sajedi, A., Smith, K. L., Parkinson, J. R. C., Ghatei, M. A., & Bloom, S. R. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.011 · Cited by 599 · cited 5×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundInfluentialvan Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 2×
“administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are”
BackgroundCork, S. C., Richards, J. E., Holt, M. K., Gribble, F. M., Reimann, F., & Trapp, S. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.07.008 · Cited by 478 · cited 6×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundMethodInfluentialYamamoto, H., Lee, C. E., Marcus, J., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L. L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15595 · Cited by 473 · cited 5×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundInfluentialYamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215595 · Cited by 429
Thomsen, W. J., Grottick, A. J., Menzaghi, F., Reyes-Saldana, H., Espitia, S., Yuskin, D., Whelan, K., Martin, M., Morgan, M., Chen, W., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.133348 · Cited by 402
Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
Sisley, S., Gutierrez-Aguilar, R., Scott, M., D’Alessio, D. A., Sandoval, D. A., & Seeley, R. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72434 · Cited by 397 · cited 22×
“afferents responded normally to the same dose of subcutaneous liraglutide used in this study (6), underscoring the importance of central GLP-1R–expressing neurons in our paradigm.”
BackgroundMethodSelf-citationBaggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2492 · Cited by 386
Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372
Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347 · cited 5×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundInfluentialEffects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312 · cited 2×
“administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are”
BackgroundMeeran, K., O’Shea, D., Edwards, C. M. B., Turton, M. D., Heath, M. M., Gunn, I., Abusnana, S., Rossi, M., Small, C. J., Goldstone, A. P., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6421 · Cited by 303 · cited 1×
“In rats, intracerebroventricular injection of a specific GLP-1R antagonist, exendin(9-39) has been shown to increase food intake in the short and long term, suggesting that neuronal GLP-1Rs contribute to normal feeding behavior (43,44).”
BackgroundEvidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
Williams, D. L., Baskin, D. G., & Schwartz, M. W. (2009) · Endocrinology · doi:10.1210/en.2008-1045 · Cited by 300 · cited 1×
“Endogenous GLP-1 can regulate feeding in the short term by signaling satiety as well as by inhibiting gastric emptying (34,48).”
BackgroundKinzig, K. P., D'Alessio, D. A., & Seeley, R. J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-23-10470.2002 · Cited by 296 · cited 6×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundSelf-citationYamamoto, H., Kishi, T., Lee, C. E., Choi, B. J., Fang, H., Hollenberg, A. N., Drucker, D. J., & Elmquist, J. K. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02939.2003 · Cited by 294 · cited 1×
“It is activated in response to peripheral administration of GLP1RAs (24,52), and liraglutide binds the AP in a GLP-1R–dependent manner (35).”
BackgroundGLP-1 and weight loss: unraveling the diverse neural circuitry
Kanoski, S. E., Hayes, M. R., & Skibicka, K. P. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00520.2015 · Cited by 290 · cited 8×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundResultInfluentialKanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C., & Hayes, M. R. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.022 · Cited by 273 · cited 7×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundInfluentialKnockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia
Krieger, J.-P., Arnold, M., Pettersen, K. G., Lossel, P., Langhans, W., & Lee, S. J. (2016) · Diabetes · doi:10.2337/db15-0973 · Cited by 269 · cited 6×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundInfluentialRüttimann, E. B., Arnold, M., Hillebrand, J. J., Geary, N., & Langhans, W. (2009) · Endocrinology · doi:10.1210/en.2008-1221 · Cited by 258 · cited 5×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundInfluentialThe Area Postrema: A Brain Monitor and Integrator of Systemic Autonomic State
Price, C. J., Hoyda, T. D., & Ferguson, A. V. (2008) · The Neuroscientist · doi:10.1177/1073858407311100 · Cited by 257 · cited 1×
“The AP is a sensory circumventricular organ known to play important roles in autonomic output, nausea, and the response to emetic drugs (51).”
BackgroundGlucagon-Like Peptide 1 Receptors in Nucleus Accumbens Affect Food Intake
Dossat, A. M., Lilly, N., Kay, K., & Williams, D. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3262-11.2011 · Cited by 256 · cited 5×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundInfluentialHayes, M. R., Bradley, L., & Grill, H. J. (2009) · Endocrinology · doi:10.1210/en.2008-1479 · Cited by 228
Stefater, M. A., Pérez–Tilve, D., Chambers, A. P., Wilson–Pérez, H. E., Sandoval, D. A., Berger, J., Toure, M., Tschöp, M., Woods, S. C., & Seeley, R. J. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.059 · Cited by 221
Self-citationHayes, M. R., Skibicka, K. P., & Grill, H. J. (2008) · Endocrinology · doi:10.1210/en.2007-1743 · Cited by 214 · cited 1×
“In addition, decerebrate rats, in which hindbrainforebrain connectivity is severed, reduced their food intake comparably with control rats after peripheral GLP1RA administration (41).”
BackgroundMcMahon, L. R., & Wellman, P. J. (1998) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1998.274.1.r23 · Cited by 199 · cited 8×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundInfluentialPreproglucagon neurons project widely to autonomic control areas in the mouse brain
Llewellyn-Smith, I. J., Reimann, F., Gribble, F. M., & Trapp, S. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.02.023 · Cited by 194 · cited 3×
“GLP-1–expressing neurons in the brainstem are glutamatergic and project to the hypothalamus (37,38).”
BackgroundBarrera, J. G., Jones, K. R., Herman, J. P., D'Alessio, D. A., Woods, S. C., & Seeley, R. J. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2212-10.2011 · Cited by 154
Self-citationControl of Food Intake and Energy Expenditure by Nos1 Neurons of the Paraventricular Hypothalamus
Sutton, A. K., Pei, H., Burnett, K. H., Myers, M. G., Rhodes, C. J., & Olson, D. P. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0226-14.2014 · Cited by 153 · cited 5×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundMethodSelf-citationBurmeister, M. A., Ayala, J. E., Smouse, H., Landivar-Rocha, A., Brown, J. D., Drucker, D. J., Stoffers, D. A., Sandoval, D. A., Seeley, R. J., & Ayala, J. E. (2017) · Diabetes · doi:10.2337/db16-1102 · Cited by 136 · cited 4×
“In rats, intracerebroventricular injection of a specific GLP-1R antagonist, exendin(9-39) has been shown to increase food intake in the short and long term, suggesting that neuronal GLP-1Rs contribute to normal feeding behavior (43,44).”
BackgroundSelf-citationAlhadeff, A. L., Baird, J.-P., Swick, J., Hayes, M. R., & Grill, H. J. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.74 · Cited by 134 · cited 1×
“The lPBN could be a candidate site for AP-independent actions of GLP1RAs because 1) it is glutamatergic, 2) it expresses GLP-1R and is activated by peripheral GLP1RAs (23,24), and 3) direct lPBN infusion of exendin-4 decreases food intake and body weight (46).”
BackgroundActivation of murine pre-proglucagon–producing neurons reduces food intake and body weight
Gaykema, R. P., Newmyer, B. A., Ottolini, M., Raje, V., Warthen, D. M., Lambeth, P. S., Niccum, M., Yao, T., Huang, Y., Schulman, I. G., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci81335 · Cited by 123
Parker, J. A., McCullough, K. A., Field, B. C. T., Minnion, J. S., Martin, N. M., Ghatei, M. A., & Bloom, S. R. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.227 · Cited by 111 · cited 6×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundResultInfluentialLachey, J. L., D’Alessio, D. A., Rinaman, L., Elmquist, J. K., Drucker, D. J., & Seeley, R. J. (2005) · Endocrinology · doi:10.1210/en.2004-0419 · Cited by 103 · cited 5×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundSelf-citationPica—A model of nausea? Species differences in response to cisplatin
Liu, Y.-L., Malik, N. M., Sanger, G. J., Friedman, M. I., & Andrews, P. L. R. (2005) · Physiology & Behavior · doi:10.1016/j.physbeh.2005.04.009 · Cited by 82 · cited 5×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundInfluentialBrain activation following peripheral administration of the GLP-1 receptor agonist exendin-4
Baraboi, E.-D., St-Pierre, D. H., Shooner, J., Timofeeva, E., & Richard, D. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00424.2010 · Cited by 79 · cited 7×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundResultInfluentialParker, L. A., Rana, S. A., & Limebeer, C. L. (2008) · Canadian Journal of Experimental Psychology / Revue canadienne de psychologie expérimentale · doi:10.1037/a0012531 · Cited by 72 · cited 4×
“In rats, intracerebroventricular injection of a specific GLP-1R antagonist, exendin(9-39) has been shown to increase food intake in the short and long term, suggesting that neuronal GLP-1Rs contribute to normal feeding behavior (43,44).”
BackgroundInfluentialZheng, H., Stornetta, R. L., Agassandian, K., & Rinaman, L. (2015) · Brain Structure and Function · doi:10.1007/s00429-014-0841-6 · Cited by 70 · cited 3×
“GLP-1–expressing neurons in the brainstem are glutamatergic and project to the hypothalamus (37,38).”
BackgroundDing, H. K., Teixeira, C. M., & Frankland, P. W. (2008) · Learning & Memory · doi:10.1101/lm.905008 · Cited by 63 · cited 5×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundMethodInfluentialGhosal, S., Packard, A. E. B., Mahbod, P., McKlveen, J. M., Seeley, R. J., Myers, B., Ulrich-Lai, Y., Smith, E. P., D'Alessio, D. A., & Herman, J. P. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1104-16.2016 · Cited by 63
Self-citationAdams, J. M., Otero-Corchon, V., Hammond, G. L., Veldhuis, J. D., Qi, N., & Low, M. J. (2015) · Endocrinology · doi:10.1210/en.2014-1429 · Cited by 50 · cited 5×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundMethodSelf-citationBurmeister, M. A., Brown, J. D., Ayala, J. E., Stoffers, D. A., Sandoval, D. A., Seeley, R. J., & Ayala, J. E. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00113.2017 · Cited by 48 · cited 4×
“In rats, intracerebroventricular injection of a specific GLP-1R antagonist, exendin(9-39) has been shown to increase food intake in the short and long term, suggesting that neuronal GLP-1Rs contribute to normal feeding behavior (43,44).”
BackgroundSelf-citationBaraboi, E.-D., Smith, P., Ferguson, A. V., & Richard, D. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00326.2009 · Cited by 46 · cited 1×
“In contrast, AP lesions in rats did not decrease the short-term anorectic or long-term weight loss effects of GLP1RAs (35,53).”
BackgroundMerchenthaler (1999) · doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5 · cited 5×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundMethodInfluential
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“The anorexigenic and weight-lowering effects of liraglutide are blunted upon genetic ablation of GLP-1R in glutamatergic neurons, yet fully preserved when GLP-1R is deleted in GABAergic neurons [718].”
BackgroundSelf-citationThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
Metadata
- Authors
- Adams, J. M., Pei, H., Sandoval, D. A., Seeley, R. J., Chang, R. B., Liberles, S. D., & Olson, D. P.
- Affiliations
- University of Michigan (US)
- Harvard University (US)
- Corresponding author
- Olson, David P.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2018-05-18
- Volume
- 67
- Issue
- 8
- Pages
- 1538-1548
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC6054439
- OpenAlex
- W2803591279
- Cited by
- 159
- References
- 57
- Citations by year
- 2026: 20 · 2025: 27 · 2024: 24 · 2023: 17 · 2022: 10 · 2021: 32 · 2020: 17 · 2019: 10 · 2018: 2
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (T32-DK-101357, DK-082480, DK-093848, DK-107652, DK-103703, DK-104999)
- Novo Nordisk
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- liraglutide, GLP-1 receptor, GLP-1 receptor agonists, glutamatergic neurons, GABAergic neurons, appetite regulation, dietary intake, weight loss, neural network activation, VGLUT2, vesicular GABA transporter
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Appetite Depressants, Energy Intake, Hypoglycemic Agents, Hypothalamus, Male, Mice, Transgenic, Nerve Net, Nerve Tissue Proteins, Neurons, Obesity, Random Allocation, Recombinant Fusion Proteins, Weight Loss, Genes, Reporter, Mice, Knockout, Green Fluorescent Proteins, Vesicular Inhibitory Amino Acid Transport Proteins, Vesicular Glutamate Transport Protein 2, Diet, High-Fat, GABAergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.